OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

A number of other analysts also recently commented on OCX. Benchmark restated a “speculative buy” rating and set a $5.00 price objective on shares of OncoCyte in a report on Monday, April 15th. Stephens restated an “equal weight” rating and set a $4.00 price target on shares of OncoCyte in a research note on Wednesday, April 17th. Finally, Needham & Company LLC lifted their price objective on OncoCyte from $3.60 to $4.25 and gave the company a “buy” rating in a research note on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.06.

OncoCyte Stock Down 0.4 %

NASDAQ OCX opened at $2.76 on Monday. The company has a 50-day moving average of $2.83 and a 200-day moving average of $3.01. OncoCyte has a 12 month low of $2.08 and a 12 month high of $5.88.

Insider Buying and Selling at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other OncoCyte news, Director Andrew Arno bought 33,898 shares of the stock in a transaction dated Thursday, April 11th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at $203,709.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders have purchased 2,457,288 shares of company stock valued at $7,176,400 over the last three months. 1.94% of the stock is owned by company insiders.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.